FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8147人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839769, encodeId=fb461839e6962, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准STAT3抑制剂WP1066治疗小儿脑癌试验的IND, objectType=article, longId=188516, objectId=a2fd1885167a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2fd1885167a, replyNumber=0, likeNumber=85, createdTime=2020-10-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2fd1885167a, moduleTitle=FDA批准STAT3抑制剂WP1066治疗小儿脑癌试验的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2fd1885167a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839742, encodeId=aa0f1839e42a3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, objectType=article, longId=183115, objectId=e7431831158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7431831158c, replyNumber=0, likeNumber=52, createdTime=2020-07-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7431831158c, moduleTitle=百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7431831158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准预填充自动注射器Fasenra治疗哮喘, objectType=article, longId=180546, objectId=25eb180546e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25eb180546e0, replyNumber=0, likeNumber=71, createdTime=2020-08-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25eb180546e0, moduleTitle=FDA批准预填充自动注射器Fasenra治疗哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25eb180546e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839740, encodeId=e4f51839e40d9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, objectType=article, longId=182505, objectId=788918250583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=788918250583, replyNumber=0, likeNumber=89, createdTime=2020-04-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=788918250583, moduleTitle=诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=788918250583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839708, encodeId=88271839e0868, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月, objectType=article, longId=177220, objectId=dcf01e7220df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf01e7220df, replyNumber=0, likeNumber=64, createdTime=2019-11-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf01e7220df, moduleTitle=诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf01e7220df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839739, encodeId=f0461839e396b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=消除胃癌潜在隐患 FDA批准创新幽门螺杆菌清除疗法上市, objectType=article, longId=182492, objectId=a42518249246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a42518249246, replyNumber=0, likeNumber=78, createdTime=2020-07-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a42518249246, moduleTitle=消除胃癌潜在隐患 FDA批准创新幽门螺杆菌清除疗法上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a42518249246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=局部用米诺环素Foamix获得FDA批准，治疗数百万中度至重度痤疮患者, objectType=article, longId=181607, objectId=95ab18160e51, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95ab18160e51, replyNumber=0, likeNumber=51, createdTime=2020-05-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95ab18160e51, moduleTitle=局部用米诺环素Foamix获得FDA批准，治疗数百万中度至重度痤疮患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95ab18160e51)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839674, encodeId=d6c618396e449, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Circassia的慢性阻塞性肺病药物喜获FDA批准, objectType=article, longId=163503, objectId=bc52163503d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc52163503d0, replyNumber=0, likeNumber=54, createdTime=2019-12-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc52163503d0, moduleTitle=Circassia的慢性阻塞性肺病药物喜获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc52163503d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839748, encodeId=60bb1839e48e6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, objectType=article, longId=183487, objectId=cbd518348e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbd518348e01, replyNumber=0, likeNumber=82, createdTime=2020-05-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbd518348e01, moduleTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbd518348e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839749, encodeId=3cbf1839e49b1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣, objectType=article, longId=183716, objectId=998c183e16c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=998c183e16c2, replyNumber=0, likeNumber=78, createdTime=2020-09-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=998c183e16c2, moduleTitle=Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=998c183e16c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839679, encodeId=410c18396e99e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, objectType=article, longId=164162, objectId=4d0c164162a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d0c164162a0, replyNumber=0, likeNumber=62, createdTime=2020-03-22, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d0c164162a0, moduleTitle=默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d0c164162a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839703, encodeId=badd1839e03ba, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Lancet Oncol：FDA批准抗肿瘤药物临床试验质量分析, objectType=article, longId=175095, objectId=b12c1e5095ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12c1e5095ac, replyNumber=0, likeNumber=75, createdTime=2020-01-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12c1e5095ac, moduleTitle=Lancet Oncol：FDA批准抗肿瘤药物临床试验质量分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12c1e5095ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839701, encodeId=ce101839e0104, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, objectType=article, longId=174802, objectId=d82e1e480215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d82e1e480215, replyNumber=0, likeNumber=66, createdTime=2020-03-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82e1e480215, moduleTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d82e1e480215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839711, encodeId=c0da1839e1117, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, objectType=article, longId=177845, objectId=6bec1e7845da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bec1e7845da, replyNumber=0, likeNumber=51, createdTime=2020-02-28, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bec1e7845da, moduleTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bec1e7845da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839663, encodeId=9e871839663ed, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准用于治疗ADHD的Adhansia XR（盐酸哌甲酯）缓释胶囊CII, objectType=article, longId=161550, objectId=2e87161550a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e87161550a1, replyNumber=0, likeNumber=90, createdTime=2019-08-25, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e87161550a1, moduleTitle=FDA批准用于治疗ADHD的Adhansia XR（盐酸哌甲酯）缓释胶囊CII, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e87161550a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839736, encodeId=7cbb1839e3689, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, objectType=article, longId=181868, objectId=ccf018186817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf018186817, replyNumber=0, likeNumber=74, createdTime=2020-02-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf018186817, moduleTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf018186817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839752, encodeId=128d1839e5201, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, objectType=article, longId=184300, objectId=0ae61843008b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae61843008b, replyNumber=0, likeNumber=70, createdTime=2020-08-22, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae61843008b, moduleTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae61843008b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839684, encodeId=12751839684ca, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变, objectType=article, longId=166172, objectId=80b21661e219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80b21661e219, replyNumber=0, likeNumber=84, createdTime=2019-09-05, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80b21661e219, moduleTitle=Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80b21661e219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839721, encodeId=38771839e21a1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, objectType=article, longId=180138, objectId=16d3180138ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d3180138ee, replyNumber=0, likeNumber=69, createdTime=2019-12-14, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d3180138ee, moduleTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d3180138ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839664, encodeId=4f171839664e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, objectType=article, longId=161781, objectId=2f85161e81f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f85161e81f8, replyNumber=0, likeNumber=64, createdTime=2019-07-13, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f85161e81f8, moduleTitle=FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f85161e81f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准STAT3抑制剂WP1066治疗小儿脑癌试验的IND

2020-10-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

百济神州的BTK抑制剂Brukinsa，成为国内获得FDA批准的抗癌药物

2020-07-31

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准预填充自动注射器Fasenra治疗哮喘

2020-08-01

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺华的长效化重组人粒细胞集落刺激因子生物仿制药Ziextenzo获得FDA批准上市

2020-04-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺华天价药存在“人为操纵数据”问题，刚获FDA批准2个月

2019-11-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

消除胃癌潜在隐患 FDA批准创新幽门螺杆菌清除疗法上市

2020-07-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

局部用米诺环素Foamix获得FDA批准，治疗数百万中度至重度痤疮患者

2020-05-16

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Circassia的慢性阻塞性肺病药物喜获FDA批准

2019-12-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物

2020-05-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Verrica制药宣布FDA批准VP-102的新药申请，用于治疗感染性软疣

2020-09-12

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

默沙东的PD-1单抗Keytruda获FDA批准治疗新的非小细胞肺癌亚型

2020-03-22

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Lancet Oncol：FDA批准抗肿瘤药物临床试验质量分析

2020-01-14

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤

2020-03-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎

2020-02-28

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准用于治疗ADHD的Adhansia XR（盐酸哌甲酯）缓释胶囊CII

2019-08-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗

2020-02-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了诺华多发性硬化症药物Gilenya的仿制药

2020-08-22

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变

2019-09-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤

2019-12-14

智者为医08 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准优先审查Celgene的JAK2抑制剂fedratinib治疗骨髓纤维化

2019-07-13

科室
- - 订阅+
  - 更多科室
工具
服务